|Year : 2023 | Volume
| Issue : 2 | Page : 54-55
Esophagogastric junction outflow obstruction – Etiology and management of a rare motility disorder
Arihant Hospital and Research Centre, Indore, Madhya Pradesh, India
|Date of Submission||19-Oct-2022|
|Date of Decision||25-Nov-2022|
|Date of Acceptance||27-Nov-2022|
|Date of Web Publication||09-Mar-2023|
297, Indrapuri, Near Bhanwarkuan, Indore, Madhya Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Jain M. Esophagogastric junction outflow obstruction – Etiology and management of a rare motility disorder. Gastroenterol Hepatol Endosc Pract 2023;3:54-5
|How to cite this URL:|
Jain M. Esophagogastric junction outflow obstruction – Etiology and management of a rare motility disorder. Gastroenterol Hepatol Endosc Pract [serial online] 2023 [cited 2023 Mar 27];3:54-5. Available from: http://www.ghepjournal.com/text.asp?2023/3/2/54/371276
Esophagogastric junction outflow obstruction (EGJOO) is a major motility disorder based on the Chicago Classification of esophageal motility disorders. It is diagnosed by performing high-resolution esophageal manometry (HREM), which shows an elevated integrated relaxation pressure with preserved peristalsis. Further, tests such as endoscopy, timed barium esophagram, and cross-sectional imaging can help to elucidate the underlying etiology and rule out mechanical causes. Potential etiologies for EGJOO include early achalasia, mechanical obstruction, extrinsic compression, infiltrative esophageal diseases, central obesity, opiate side effects, and postfundoplication status.,,,
The present retrospective study was done at Arihant Hospital and Research Centre, Indore, to determine the frequency of EGJOO among patients undergoing HREM for a variety of indications. Moreover, the cause of EGJOO, treatment offered, and response to treatment was analyzed. This retrospective study included all patients diagnosed with EGJOO between January 2015 and June 2019. Mechanical reasons for EGJOO were ruled out using upper gastrointestinal endoscopy and computed tomography (CT), whenever necessary. Before HREM, medications that are likely to affect smooth muscle contraction or lower esophageal sphincter relaxation, such as prokinetics and anticholinergics, were withdrawn for 14 days. Informed consent was obtained from all patients. HREM recording was done using 5 mL water for 10 swallows in the supine posture, using 16-channel water-perfusion system (Ready Stock, Australia) and reporting was done using Trace 1.3.3 software (Hebbard, Australia) with Chicago classification version 3.0. The study was approved by the institutional ethics committee. For statistical analysis, the data were expressed as percentages, medians, and ranges. Comparison of medians was done using Mann–Whitney U test and the comparison of proportions was done using the Chi-square test. A P < 0.05 was considered statistically significant.
A total of 168 hEM studies were done by the author during the study period. Of these, 12 patients (7.2%) had features suggestive of EGJOO [Figure 1]. The median age was 42 years (range 21–56) and males outnumbered females (5:1). The comorbid states included diabetes (3), hypertension (2), and hypothyroidism (2). The symptoms reported included – dysphagia for solids and/or liquids (11, 91.7%), chest pain (7, 58.4%), and weight loss (3, 25%). Mechanical causes of EGJOO were noted in six patients (all males). These included postfundoplication status (5) and benign esophageal stricture (1). All patients with mechanical EGJOO underwent endoscopic balloon dilatation up to 15 mm with good resolution of symptoms on follow-up. In six cases with functional EGJOO, medical management was offered. Four patients (three males and one female) had central obesity and a history of weight gain in the preceding 1 year. They were started on proton-pump inhibitors. Moreover, weight loss with diet control and regular aerobic exercises for 30 min per day was advised. On follow-up at 3 months, they lost an average of 3.5 kg weight, and all reported significant improvement in symptoms. In two patients (one male) with functional EGJOO and no central obesity, acotiamide was initiated in a dose of 100 mg thrice a day. On follow-up at 1 month, there was a significant improvement in symptoms in these two cases. None of the patients reported progression of symptoms and required endoscopic interventions in the functional EGJOO. There was no significant difference in the age and symptoms at presentation in the two groups – mechanical and functional EGJOO [Table 1]. However, the median distal contractile integral was higher in patients with functional EGJOO.
|Figure 1: Manometry image of EGJOO. EGJOO: Esophagogastric junction outflow obstruction|
Click here to view
|Table 1: Comparison of demographic and high-resolution esophageal manometry parameters between mechanical and functional esophagogastric junction outflow obstruction|
Click here to view
To summarize, EGJOO was noted in 7.2% of all cases undergoing HREM. Mechanical causes were noted in 50% of cases and the majority were secondary to fundoplication surgery. All cases responded well to endoscopic balloon dilatation. Functional EGJOO was more common in patients with central obesity and weight gain. The use of proton-pump inhibitors and lifestyle improvement caused significant improvement in symptoms. Acotiamide was beneficial in patients with functional EGJOO with no central obesity.
The present retrospective study offers insight into the management and outcome of patients with EGJOO. This rare motility disorder is well documented. However, there is no consensus on its proper management. In addition to endoscopy and HREM, other tests such as timed barium swallow, functional luminal imaging probe, endoscopic ultrasound, and CT scan help to point to a certain etiology in EGJOO. Functional EGJOO usually has a benign course as noted in previous studies., A recent study noted that acotiamide potentially normalizes the impaired LES relaxation in patients with EGJOO, with no adverse effects on normal esophageal motility patterns.
The present study is limited by its small sample size and retrospective design. Moreover, repeat HREM studies and timed barium swallows were not done to document improvement in EGJOO. Despite this, it throws light on a rare motility disorder which is often neglected. Multicentric studies are required to determine guidelines for the proper management of patients with EGJOO.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, et al.
The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015;27:160-74.
Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol 2019;25:411-7.
Kahrilas PJ, Bredenoord AJ, Carlson DA, Pandolfino JE. Advances in management of esophageal motility disorders. Clin Gastroenterol Hepatol 2018;16:1692-700.
Okeke FC, Raja S, Lynch KL, Dhalla S, Nandwani M, Stein EM, et al.
What is the clinical significance of esophagogastric junction outflow obstruction? evaluation of 60 patients at a tertiary referral center. Neurogastroenterol Motil 2017;29. doi: 10.1111/nmo.13061.
Schupack D, Katzka DA, Geno DM, Ravi K. The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry. Neurogastroenterol Motil 2017;29:1-9.
Ratuapli SK, Crowell MD, DiBaise JK, Vela MF, Ramirez FC, Burdick GE, et al.
Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol 2015;110:979-84.
Carlson DA, Gyawali CP. Is high-resolution manometry always needed for the diagnosis of achalasia? Clin Gastroenterol Hepatol 2018;16:480-2.
Pérez-Fernández MT, Santander C, Marinero A, Burgos-Santamaría D, Chavarría-Herbozo C. Characterization and follow-up of esophagogastric junction outflow obstruction detected by high resolution manometry. Neurogastroenterol Motil 2016;28:116-26.
Muta K, Ihara E, Fukaura K, Tsuchida O, Ochiai T, Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: A pilot study. Digestion 2016;94:9-16.